Fast Five Quiz: Do You Know What to Watch for and How Best to Treat Diabetic Foot Ulcers?

Vincent Lopez Rowe, MD

Disclosures

December 15, 2014

Becaplermin gel 0.01% (Regranex®), a recombinant human platelet-derived growth factor that is produced through genetic engineering, is approved by the US Food and Drug Administration to promote healing of diabetic foot ulcers. Regranex is meant for a healthy, granulating wound, not one with a necrotic wound base, and is contraindicated with known skin cancers at the site of application.

Debriding agents, such as collagenase, are useful for necrotic wounds as an adjunct to surgical debridement. However, debriding agents are only useful if the arterial supply to the foot is normal. In patients with peripheral arterial disease, a debriding agent removes both the healthy and necrotic tissue. Hydrocolloids are useful for dry necrotic wounds, wounds having minimal exudate, and clean granulating wounds. Hydrogel is useful for dry, sloughy, necrotic wounds (eschar).

For more on the treatment for diabetic ulcers, read here.

Related Resources

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....